- 0.2% of patients with congenital hemophilia with inhibitors experienced thrombotic adverse events in clinical trials1
- 4% of patients with acquired hemophilia experienced thrombotic events1
- <0.2% thrombotic events reported in patients with Glanzmann's thrombasthenia1,a
Safety profile for your patients.
With a proven low rate of thrombotic events and recombinant manufacturing, your patients can rely on the safety profile of NovoSeven® RT.1,2
A proven low rate of thrombotic adverse events.
The only recombinant option for all indicated patients.
- Undergoes a 5-step purification process1,3
- The only bypassing agent not made from human serum or human proteins1
- Recombinant manufacturing minimizes the possibility of viral contamination4

aIn clinical trials and registries used to support licensure and in postmarketing surveillance, the overall rate of thrombosis was 0.19% of 518 bleeds.5
Contains only rFVIIa.1
NovoSeven® RT is the only bypassing agent not made with any other coagulation factors, such as FIX or FIXa.1,6

MASAC recommends patients with congenital hemophilia B with a history of inhibitors and anaphylaxis not be given FIX-containing products unless bleeding is life-threatening.7
MASAC=Medical and Scientific Advisory Council
The NovoSeven® RT 5-step production and purification process.
Developed in a baby hamster kidney (BHK) cell line.


STEP 1
The working cell bank
Cells are genetically engineered to express rFVIIa.3
STEP 2
Fermentation
Culture media containing newborn calf serum are used to increase the volume of the culture.3
STEP 3
Purification
Centrifugation and filtration remove host cell proteins along with serum and medium components.3
STEP 4
Formulation and freeze-drying
Formulation and sterile filtering; then it is put in to sterile vials and freeze-dried to make a low-volume powder.3
STEP 5
Final inspection
Detailed quality inspection ensures the manufacturing process observes the highest standards of purity.3
Abbreviated representation of the NovoSeven® RT manufacturing process.
![NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) Mechanism of Action video](/content/dam/novonordisk/novosevenpro/cta/novoseven-mechanism-of-action-video.jpg)
See how NovoSeven® RT
for CHwI works.

Approved for bleed management and
surgical use in 4 indicated disorders.
